Partner With Us
Innovation Through Collaboration
Advance your product development through collaboration with Glen Clova Scientific. Unlock challenging targets using our next-generation VLP technology and drive your pipeline forward.
Innovation thrives on partnership, shared expertise, and purposeful collaboration. Glen Clova Scientific’s proprietary VLP platform is designed to help biopharma and diagnostics companies accelerate discovery, overcome development bottlenecks, and deliver differentiated products to market.
GCS can be the key to overcoming current challenges in antibody engineering, vaccine development, or antigen design. Our bioengineering experts work closely with partners to design and implement VLP-based solutions that make a measurable impact.
Comprehensive. Versatile. Scalable.
Strategic Industry Partnerships
Every collaboration begins with a shared objective — to translate innovative VLP applications into meaningful commercial outcomes.
Collaborative Research
We work with biopharma partners to co-develop next-generation therapeutics, vaccines, and immune-targeting modalities using our modular VLP platform. Whether you are exploring complex targets or enhancing delivery, we will tailor a programme around your goals.
VLP Programmes
Glen Clova Scientific programmes are available for licence on a worldwide or regional basis. We offer flexible deal structures, including exclusive options for early-stage programmes and co-development opportunities designed to accelerate your innovation.
Platform Licensing
Our patented system brings a new level of versatility to class-leading bioproduction. The GCS platform is ready to support your innovation — contact us to learn what we could do for your business.
Diagnostic Applications
Our VLP technology provides new levels of precision for immunoassay and biomarker development. We collaborate with diagnostic innovators to create sensitive, stable, and scalable solutions that enhance test performance..
Introducing EPIclip™
A modular, platform that presents complete, native-folded proteins on virus-like particle surfaces — achieving durable immunity while keeping autoreactive T cells silent.
One host. One step. Full decoration.
01
Modular by Design
Swap the surface antigen without rebuilding the platform. EPIclip™ is engineered to accept virtually any target protein — enabling rapid pipeline expansion across human and veterinary indications.
02
Authentically Folded
Unlike peptide display, EPIclip™ presents full-length, natively structured proteins — preserving the conformational epitopes needed for biologically meaningful antibody responses.
03
Safety-First Immunity
Potent IgG with no autoreactive T cells detected. Engineered to focus the immune response on antibody production — critical when targeting proteins in therapeutic vaccine design.